



Biosecurity Is A Priority at Inscripta

Introduction:

Inscripta's technology and products allow for digital genome engineering on an unprecedented scale. We are committed to ensuring this is done in a safe, responsible, and ethical way.


Our biosecurity systems include procedures intended to protect humans and other organisms against potential harm from biological agents. The biorisk scenarios that we consider are:

- Deliberate: bioterrorist, very rare, yet may be devastating if it happens
 - We screen customers
- Accidental: biology is complex so there may be unforeseen results of certain edits
 - Eg. Short insert in genomic context encodes an intact toxin
 - We screen design libraries before production
- Dual Use: legitimate research that could also be used for a harmful purpose
 - Eg. Toxins are studied for potential medicinal value; approval needed
 - We communicate with customers

Inscripta partners with customers to ensure everyone's safety!

Purpose of our Biosecurity Processes:

Our multipronged system is designed to proactively detect and prevent biorisk. This includes screening customers and platform users, genomes that users upload that are not an Inscripta Strain, as well as screening every Design Library ordered.



Customer screening blocks known bad actors, individuals on government banned list, that are most likely to have nefarious intentions. We follow industry standard practices and anticipate virtually zero matches.

We trust approved customers, so ***in silico* sequence screening** primarily targets accidental creation of a biorisk or a dual use scenario. We computationally screen custom genomes, to ensure they are Inscripta approved strains and also a first pass at biorisk detection, comparing against known genes that may cause harm. The next phase is an ***in silico*** screen of all customer directed edits, using a functional biorisk prediction algorithm. Matches will invoke manual verification and, if warranted, dialogue with customers to redesign or pursue authorization.

Our biosecurity screening goals are to ensure everyone's safety while also having minimal impact on customer workflow. Hence, the following features:


- **Proactive:** Identify the biorisk before reagents are developed
- **Confidentiality** of screening data: *in silico* screening is carried out in-house at Inscripta
- **Speed:** Screening is fast and designed to be in parallel with other processes, so that in normal situations, biosecurity is not invoking a delay
- **Collaborative:** We partner with our customers. In the event of biosecurity alerts, our Customer Success Team will mediate discussions with customers to remedy the situation

Practicalities and customer involvement:

Customer screening requires four pieces of information supplied by the instrument purchaser and each individual user who will create and order design libraries:

1. First and last name, 2. Agency, 3. Official email, 4. Complete physical shipping address

A look at the biosecurity processes in the context of the user journey to discovery:



Custom genome screening begins upon upload by the user. If uploaded genome is an unapproved strain or if a biorisk is identified, the Customer Success Team, led by a Field Application Scientist (FAS) with input from Biosecurity Team as relevant, will hold conversations to assist the customer alleviate the situation.

Design library screening begins upon submission for a quote request. Biosecurity alerts will likewise trigger customer reach back by Customer Success Team (with involvement of the Biosecurity Team) to discuss and reach a solution to remedy the biosecurity concern. Passing of this screen allows design libraries to safely move forward to production.

In summary: Our biosecurity processes aim to identify and prevent biorisk while minimizing impact upon customers. Safety and responsibility are the highest priority at Inscripta!